Gilead Sciences, Inc. (GILD)’s EVP Comm&Acs ALA – Corp&Med Aff Gregg Alton Sold 30,000 Shares of the Company; Shelton Capital Management Decreased Ing Groep N V (ING) Position By $778,158

Stock trade totalling approx. $2,370,000 USD was reported in a document submitted to the Security and Exchange Commission on January 16, 2018. According to which, Gregg Alton, the EVP Comm&Acs ALA – Corp&Med Aff of Gilead Sciences Inc also an insider of the corporation had unloaded precisely 30,000 shares – ( at $79.0 a share ). This is not his first insider trade, in the last month, he sold another 15,000 shares worth $1,108,019 USD. Today, he has rights to a total of 45,488 shares or 0.00% of the company’s market capitalization. It is an important deal and hence it will very likely not remain undiscovered.

Shelton Capital Management decreased Ing Groep N V (ING) stake by 33.93% reported in 2017Q3 SEC filing. Shelton Capital Management sold 43,231 shares as Ing Groep N V (ING)’s stock rose 17.61%. The Shelton Capital Management holds 84,195 shares with $1.55M value, down from 127,426 last quarter. Ing Groep N V now has $76.97 billion valuation. The stock decreased 0.69% or $0.14 during the last trading session, reaching $20.17. About 3.15M shares traded or 23.84% up from the average. ING Groep N.V. (NYSE:ING) has risen 45.69% since January 17, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. They expect $1.67 earnings per share, down 36.74% or $0.97 from last year’s $2.64 per share. GILD’s profit will be $2.18B for 12.01 P/E if the $1.67 EPS becomes a reality. After $2.23 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.11% negative EPS growth.

Since August 1, 2017, it had 0 insider purchases, and 11 sales for $41.13 million activity. On Thursday, August 31 the insider MARTIN JOHN C sold $6.09M. Meyers James R had sold 60,000 shares worth $4.99 million on Thursday, August 31. Alton Gregg H sold 50,000 shares worth $3.95 million. On Thursday, September 7 Washington Robin L sold $4.40M worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 51,820 shares.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. It improved, as 96 investors sold Gilead Sciences, Inc. shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Kames Capital Public Limited Co owns 449,753 shares for 1% of their portfolio. Fortaleza Asset Mngmt has invested 2.35% in Gilead Sciences, Inc. (NASDAQ:GILD). Glenmede Trust Na holds 0.22% in Gilead Sciences, Inc. (NASDAQ:GILD) or 623,506 shares. Fmr Lc reported 0.27% in Gilead Sciences, Inc. (NASDAQ:GILD). Cullinan Assoc Incorporated holds 0.07% or 11,250 shares. 48,050 were accumulated by Clark Estates. Toronto Dominion Bancorp owns 517,768 shares or 0.13% of their US portfolio. Nebraska-based Ameritas Investment Partners has invested 0.27% in Gilead Sciences, Inc. (NASDAQ:GILD). Bbva Compass Fincl Bank invested in 13,357 shares. Keybank Natl Association Oh reported 0.26% stake. Palouse Cap Mngmt Incorporated stated it has 2.51% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Md Sass Invsts holds 2.35% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 346,515 shares. Westend Advsr Limited Liability Company accumulated 701,463 shares. Raymond James Assoc reported 969,419 shares. Endurant Mngmt Lp holds 0.67% or 27,357 shares.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company has market cap of $104.83 billion. The company??s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It has a 9.13 P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

The stock increased 1.56% or $1.23 during the last trading session, reaching $80.25. About 11.75M shares traded or 41.71% up from the average. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 17, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $97.04’s average target is 20.92% above currents $80.25 stock price. Gilead Sciences had 112 analyst reports since July 29, 2015 according to SRatingsIntel. The company was downgraded on Friday, April 29 by Maxim Group. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Piper Jaffray on Tuesday, July 25. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, October 6. Leerink Swann maintained it with “Market Perform” rating and $89 target in Thursday, October 5 report. Jefferies initiated it with “Hold” rating and $115 target in Wednesday, September 9 report. The firm earned “Buy” rating on Friday, April 29 by UBS. The rating was upgraded by Piper Jaffray on Thursday, November 5 to “Overweight”. The company was upgraded on Tuesday, January 16 by Wells Fargo. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Tuesday, November 8 by Mizuho. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Friday, October 2 report.

Shelton Capital Management increased Amgen Inc (NASDAQ:AMGN) stake by 2,809 shares to 72,293 valued at $13.48M in 2017Q3. It also upped Kellogg Co (NYSE:K) stake by 54,500 shares and now owns 301,416 shares. Viacom Inc New (NASDAQ:VIAB) was raised too.